Barclays analyst Matt Miksic lowered the firm’s price target on Zimmer Biomet (ZBH) to $118 from $125 and keeps an Underweight rating on the shares. The firm updated its moddel to reflect more significant share repurchases and tougher currency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Citi opens ‘positive catalyst watch’ on Zimmer Biomet
- Zimmer announces FDA clearance of Persona SoluTion Porous Plasma Spray Femur
- Zimmer Biomet assumed with an Equal Weight at Morgan Stanley
- Zimmer Biomet receives FDA approval for Oxford Cementless Partial Knee
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules